The Cognitive Variability in NF1 and TSC Monozygotic Twins

Learn more about:
Related Clinical Trial
Doxycycline In Lymphangioleiomyomatosis (LAM) Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women Turmeric as Treatment in Epilepsy Study of the Disease Process of Lymphangioleiomyomatosis RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM The Effectiveness and Safety of Vagus Nerve Stimulation for TRE The Effectiveness and Safety of Resective Epilepsy Surgery for TRE Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) Safety of Simvastatin in LAM and TSC Studies of Autistic Patients: Gene Networks and Clinical Subtypes Topical Rapamycin to Erase Angiofibromas in TSC Rapalogues for Autism Phenotype in TSC: A Feasibility Study A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD Everolimus for Cancer With TSC1 or TSC2 Mutation Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex The Cognitive Variability in NF1 and TSC Monozygotic Twins Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy – Tuberous Sclerosis Complex A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC) Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex JASPER Early Intervention for Tuberous Sclerosis Studies in Patients With Tuberous Sclerosis Complex Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex (TuScCom) Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC) Tuberous Sclerosis Complex Natural History Study: Renal Manifestations Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) Study of Skin Tumors in Tuberous Sclerosis

Brief Title

The Cognitive Variability in NF1 and TSC Monozygotic Twins

Official Title

The Cognitive Variability in Neurofibromatosis Type I and Tuberous Sclerosis Complex Monozygotic Twins

Brief Summary

      Both Neurofibromatosis type 1 (NF1) and Tuberous Sclerosis Complex (TSC) are highly
      heterogeneous diseases. Cognitive features seem to vary widely even between family members
      carrying the same mutation. This phenotypic variability is not well understood, but is
      generally assumed to be caused by modifier genes which regulate the affected pathways.
      However, recent studies brought forward an alternative explanation for the phenotypic
      variability. Post-mortem studies showed that second hit mutations causing loss of the second
      ('healthy') allele are more widespread than previously believed. These loss of heterozygosity
      (LOH) mutations cause bi-allelic loss of the disease-linked gene and are known to cause the
      gross of somatic features in both diseases (like neurofibromas and hamartomas). Hence, it
      could be the stochastic occurrence of second-hit mutations in the brain are the cause of the
      variable cognitive phenotypes.

      To investigate to what extent these LOH mutations in the brain contribute to the phenotype
      and to what extent this variation is due to genetic modifiers factors is unknown. The
      investigators therefore propose to elucidate this variability by comparing the correlation of
      cognitive features of monozygotic twins with NF1 or TSC to healthy twins in the population.
      If modifier genes are the cause of the variability of cognitive features in NF1 and TSC the
      investigators expect that the variability in cognitive tests in monozygotic twins is the same
      as monozygotic twins in the healthy population. However, if the variability is caused by the
      occurrence of LOH mutations, the investigators expect to have a lower correlation in our
      monozygotic patients compared to the healthy twins.
    



Study Type

Observational


Primary Outcome

Correlation of full intelligence quotient

Secondary Outcome

 Correlation of word reading ability

Condition

Neurofibromatosis Type I


Study Arms / Comparison Groups

 Neurofibromatosis type I (NF1)
Description:  Monozygotic twin pairs with genetically confirmed Neurofibromatosis type I

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

116

Start Date

April 2015

Completion Date

April 2017

Primary Completion Date

April 2017

Eligibility Criteria

        Inclusion Criteria:

          -  The participant is part of a monozygotic twin pair (which is genetically confirmed);

          -  NF1 or TSC patients with a genetically confirmed diagnosis;

          -  Oral and written informed consent by participant in case ≥ 18 years of age.

          -  Oral and written informed consent by both caregivers and assent by participant in case
             of minor participants.

        Exclusion Criteria:

          -  A potential subject of whom the twin sibling is not willing or able to participate in
             this study, will be excluded from participation in this study.

          -  Symptomatic brain pathology.
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

Ype Elgersma, Prof., +31 10 7037739, [email protected]

Location Countries

Netherlands

Location Countries

Netherlands

Administrative Informations


NCT ID

NCT02436746

Organization ID

MEC-2014-483


Responsible Party

Principal Investigator

Study Sponsor

Erasmus Medical Center


Study Sponsor

Ype Elgersma, Prof., Principal Investigator, Erasmus MC


Verification Date

May 2015